TXG — 10x Genomics, Inc.

Is TXG overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Health Information Services

Oversold As of August 19, 2026

10x Genomics, Inc. (TXG) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Health Information Services) last closed at $55.63. The rating moved from Neutral to Oversold on August 19, 2026.

See all oversold Healthcare stocks →

AI analysis

10x Genomics is positioned as a leader in single-cell and spatial genomics with a consumables-driven revenue model that supports recurring revenue and margin improvement as installed instruments proliferate. Product innovation and expanding genomic and diagnostics use-cases create meaningful growth optionality, particularly given favorable market sentiment for growth and diagnostics/AI tailwinds. However, the company remains exposed to execution and cash-flow risk, competitive pressure, and dependence on lab capital spending. Near-term price action is likely to be driven by sentiment, quarterly execution, and any updates on revenue cadence and profitability trajectory.

Key factors

  • Market leadership in single-cell and spatial genomics platforms with strong install base driving recurring consumables and reagents revenue.
  • Large and expanding addressable market as genomic applications broaden across oncology, immunology, and spatial-transcriptomics-driven diagnostics.
  • Recurring consumables model provides revenue visibility and margin expansion potential as installed base grows.
  • Ongoing product innovation and partnerships that increase utility of platform for translational research and clinical adoption.
  • Current risk-on market sentiment and diagnostics/AI tailwinds may lift growth-oriented, high-beta names like TXG in the near term.
  • Operational leverage potential as R&D and SG&A scale relative to revenue growth could improve margins over 12–24 months.

Risks

  • Sustained unprofitability and cash burn could force dilutive financing if revenue growth or margin improvement lags expectations.
  • Intense competition from established sequencing and instrument vendors and emerging single-cell technologies could compress pricing and share.
  • Adoption-dependent business model; slower-than-expected clinical translation or slower capital spending by labs could reduce consumables upside.
  • Supply-chain disruptions or reagent shortages could constrain instrument installs and consumables revenue.
  • Macroeconomic weakness or reduced research budgets at academic and pharma customers could slow orders for capital equipment.
  • Execution risk around scaling manufacturing, international expansion, and converting research use into clinical/reimbursement pathways.

See today's live rating, score and targets

Members see the live hourly rating for TXG — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.